Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Current Assets (2022 - 2025)

bioAffinity Technologies (BIAF) has disclosed Current Assets for 4 consecutive years, with $8.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Current Assets rose 237.9% to $8.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $8.6 million, a 237.9% increase, with the full-year FY2024 number at $2.7 million, down 32.16% from a year prior.
  • Current Assets was $8.6 million for Q3 2025 at bioAffinity Technologies, up from $1.7 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $14.1 million in Q3 2022 to a low of $1.7 million in Q2 2025.
  • A 4-year average of $6.1 million and a median of $4.0 million in 2023 define the central range for Current Assets.
  • Peak YoY movement for Current Assets: crashed 69.05% in 2024, then surged 237.9% in 2025.
  • bioAffinity Technologies' Current Assets stood at $12.0 million in 2022, then tumbled by 66.79% to $4.0 million in 2023, then crashed by 32.16% to $2.7 million in 2024, then surged by 219.6% to $8.6 million in 2025.
  • Per Business Quant, the three most recent readings for BIAF's Current Assets are $8.6 million (Q3 2025), $1.7 million (Q2 2025), and $1.9 million (Q1 2025).